Trials / Unknown
UnknownNCT06317142
Glucose and Glycogen Dynamics in Prediabetes
Investigating Disturbances in Glucose and Glycogen Dynamics in Prediabetes
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The goal of this observational study is to investigate changes in nocturnal and postprandial glucose and glycogen metabolism in individuals with impaired fasting glucose and impaired glucose tolerance compared to healthy, non-diabetic, overweight participants (15 per group). In addition, it will be investigated if reducing gluconeogenesis, by using the challenge agent Acipimox, in people with prediabetes can increase glucose tolerance and fat oxidation by increased reliance on hepatic glycogen. The main questions this project aims to answer are: * whether there are differences in nocturnal glucose/glycogen metabolism in individuals with impaired fasting glucose, impaired glucose tolerance and healthy overweight controls. * whether there are differences in postprandial glucose/glycogen metabolism in individuals with impaired fasting glucose, impaired glucose tolerance and healthy overweight controls. Participants will visit the university for a screening visit and a visit with overnight stay for measurements of gluconeogenesis, glycogen, and substrate oxidation. A subgroup will receive \[18F\]-FDG to assess tissue-specific postprandial glucose uptake. Thereafter, 20 prediabetic individuals will follow a 4-day treatment with acipimox to decrease gluconeogenesis, followed by a second overnight visit with similar measurements as mentioned for the first visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acipimox 250 mg Oral Capsule | A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4. |
Timeline
- Start date
- 2024-02-20
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2024-03-19
- Last updated
- 2024-04-09
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT06317142. Inclusion in this directory is not an endorsement.